Appendix Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the appendix, characterized by the presence of mucinous stroma formation. 
Appendix mucinous adenocarcinomas most frequently harbor alterations in KRAS, TP53, SMAD4, TGFBR2, and APC .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, KRAS G12D, and TP53 Mutation are the most common alterations in appendix mucinous adenocarcinoma .
There is 1 clinical trial for appendix mucinous adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains appendix mucinous adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in appendix mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.